News

UK Biotech & Life Sciences News

Follow the latest UK life sciences company news, including biotech funding rounds, pharma partnerships, product launches, clinical updates, infrastructure projects and commercial announcements.

Latest updates
Showing 37–48 of 243 stories

BioUK Acquires Selected SEHTA Assets to Expand Medtech and Healthtech Support

BioUK has acquired selected assets of the Science and Engineering Health Technologies Alliance (SEHTA) through an asset purchase agreement, expanding its support for UK medtech and healthtech SMEs. SEHTA's brand and elements of its member-support activities will be incorporated into BioUK, with SEHTA staff supporting the transition; the announcement does not describe an acquisition of the whole SEHTA legal entity.

Qureight's Fibr8 Imaging Biomarker Selected for Contineum's Phase 2 PROPEL-IPF Trial

Cambridge-based Qureight's Fibr8 quantitative CT imaging biomarker has been selected as a secondary endpoint in Contineum Therapeutics' Phase 2 PROPEL-IPF trial of PIPE-791 in idiopathic pulmonary fibrosis. The trial plans to enrol approximately 324 patients and will assess structural lung fibrosis alongside its primary lung-function endpoint; the partnership does not itself establish treatment efficacy.

Cell and Gene Therapy Catapult CEO Matthew Durdy to Retire in June 2027

Cell and Gene Therapy Catapult has announced that CEO Matthew Durdy intends to retire in June 2027 after nearly 15 years with the organisation, including seven as chief executive. Durdy will remain in post during the transition, and the board has engaged Coulter Partners to support its search for a successor; no replacement has yet been announced.

Valneva Reports Positive Phase 2 Results for Shigella Vaccine Candidate S4V2

Valneva has reported positive results from two Phase 2 trials of S4V2, its tetravalent Shigella vaccine candidate. A controlled human infection study in about 120 adults met its primary endpoint with a statistically significant reduction in shigellosis versus placebo, and a trial in 110 infants in Kenya showed a significant antibody response. Valneva is reviewing the full data to decide next steps.

Immunocore Reports Phase 1/2 Brenetafusp and KIMMTRAK Data in Uveal Melanoma

Immunocore has presented Phase 1/2 data at SITC for brenetafusp combined with KIMMTRAK in first-line metastatic uveal melanoma. Among 17 evaluable patients the overall response rate was 29%, with 88% alive at one year and 70% at two years, and no Grade 3 or 4 cytokine release syndrome. The company plans to start a randomised Phase 2/3 trial, DUET-UVEAL.

Oxford BioDynamics Signs First Pharma Deal with Johnson & Johnson for Orion

Oxford BioDynamics has signed its first commercial agreement with a pharmaceutical company, Johnson & Johnson, for its EpiSwitch Orion 3D genomics platform. OBD will run a biomarker discovery programme in inflammatory bowel disease to identify features that may predict response to biologic therapies, using several hundred genotyped patient samples. Financial terms are confidential.

Resolution Therapeutics Reports Positive Interim EMERALD Data for RTX001 in Liver Disease

Resolution Therapeutics has reported six-month interim Phase I/II EMERALD data for RTX001, an engineered macrophage therapy for end-stage liver disease. Against an external control, the first nine patients showed a 42% relative risk reduction in death, liver transplant or hepatic decompensation. The company plans a pivotal US trial, with a pre-IND meeting with the FDA scheduled for December 2026.

Alethio Therapeutics Raises $90m Series A for Blood Cancer Antibody ATX-011

Oxford spinout Alethio Therapeutics has raised $90m (£67m) in an oversubscribed Series A co-led by Sofinnova Partners and RA Capital, with Oxford Science Enterprises, Cancer Research Horizons and the University of Oxford also taking part. The money will take ATX-011, a first-in-class therapy for essential thrombocythaemia, through Phase 1/2a studies and advance further myeloproliferative neoplasm programmes towards IND submission.